ARMAGEN TECHNOLOGIES, INC.

Basic Information

26679 Agoura Rd., #100
CALABASAS, CA, 91302-3811

http://www.armagen.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 137142589
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 9


  1. Sulfamidase Brain Drug Delivery in Sanfilippo Syndrome

    Amount: $152,138.00

    DESCRIPTION (provided by applicant): Mucopolysaccharidosis (MPS) Type IIIA, also called Sanfilippo A syndrome, is a genetic disease caused by mutations in the gene encoding the lysosomal enzyme, N-su ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein

    Amount: $981,134.00

    DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)-alpha plays a pro-inflammatory role in aging-related neurodegenerative diseases, such as Alzheimer's disease or Parkinson's ...

    SBIR Phase II 2013 Department of Health and Human Services
  3. Metachromatic Leukodystrophy Enzyme Drug Development

    Amount: $999,645.00

    DESCRIPTION (provided by applicant): Metachromatic Leukodystrophy or MLD, is a genetic disease that affects the lysosomal enzyme, arylsulfatase A (ASA). People born with MLD develop extensive lysosoma ...

    SBIR Phase II 2013 Department of Health and Human Services
  4. Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II

    Amount: $1,052,435.00

    DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is a genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). Con ...

    SBIR Phase II 2012 Department of Health and Human Services
  5. Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein

    Amount: $148,530.00

    DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)- plays a pro-inflammatory role in brain diseases. The biologic TNF inhibitors (TNFI), such as the TNF decoy receptor cannot be develop ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Metachromatic Leukodystrophy Enzyme Drug Development

    Amount: $156,555.00

    DESCRIPTION (provided by applicant): Metachromatic leukodystrophy (MLD) is an genetic disease caused by mutations in the gene encoding the lysosomal enzyme, arylsulfatase A (ASA). Symptoms including n ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II

    Amount: $111,214.00

    DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is an genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). C ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. Re-Engineering Blood-Borne Erythropoietin for Targeted Delivery

    Amount: $149,800.00

    DESCRIPTION (provided by applicant): Erythropoietin (EPO) is a potential new pharmaceutical to treat vascular disease of the brain, including stroke. However, EPO is a large molecule pharmaceutical th ...

    SBIR Phase I 2011 Department of Health and Human Services
  9. Bioengineering of a New Antibody Drug Delivery Technology

    Amount: $849,582.00

    DESCRIPTION (provided by applicant): Monoclonal antibodies (MAb) are potential new therapeutics for many brain diseases, including Alzheimer's disease (AD), Parkinson's disease, mad cow dise ...

    SBIR Phase II 2011 Department of Health and Human Services
  10. Bioengineering of a New Decoy Receptor Drug Delivery Technology

    Amount: $111,999.00

    DESCRIPTION (provided by applicant): Decoy receptors are potential new pharmaceuticals to treat brain diseases, such as brain injury, spinal cord injury, stroke, or neurodegeneration. However, decoy r ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government